Cytosorbents (NASDAQ: CTSO)
$0.91
(1.1%)
$0.01
Price as of December 31, 2024, 4:00 p.m. ET
Cytosorbents Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cytosorbents Company Info
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
News & Analysis
Featured Article
Here's Why Cytosorbents Is Up 17% Today
The biotech company took another step toward introducing a new way of performing bypass surgeries.
James Brumley | Jul 6, 2021
Featured Article
Why CytoSorbents Is Soaring 12% Today
The company's priced its recently announced stock offering.
Todd Campbell | Jul 22, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.